BCL2 and leukemia: Therefore, it is not surprising that the targeting of OXPHOS via the BCL-2 inhibitor venetoclax in combination with the hypomethylating agent azacitidine was able to impair leukemia stem cells (LSCs) proliferation and metabolic activity (Jones et al., 2018; Pollyea et al., 2018).